Scynexis’ Phase III Success Brings New Antifungal Class Closer To Approval

 
• By Joseph Haas
  
SC1911_Candida-auris-fungi_1164101620_1200.jpg
Ibrexafungerp is being developed for acute and recurrent VVC
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business